Originally published byEU-Startups
Xeltis, a commercial-stage MedTech company based in the Netherlands and the USA, developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue, has raised an additional €20.5 million in new funding. This funding was secured from new and existing shareholders. The round was led by new investor Horizon 3 Healthcare, […]
The post Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissue appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
Cloud giants pour nearly $600B into capex as AI demand surges
14h ago
As Larry Ellison bets the farm, Oracle says it loves AI-written code, just not in OpenJDK
1d ago
UK government investment arm cops to 40-hour leak of officials' contact details
1d ago
IT boss left root session open for bring-your-kid-to-work day
1d ago
Sci-fi authors Scalzi and Stross decry AI's dystopian impact on their craft
1d ago